Statin Applications in Gynecological Cancer Management

Statins, first developed as lipid-lowering agents, have emerged as promising adjuncts in the management of gynecological malignancies, particularly ovarian cancer. By inhibiting HMG-CoA reductase, statins disrupt the mevalonate pathway, a metabolic cascade critical for cholesterol biosynthesis and the prenylation of signalling proteins. Preclinical studies have demonstrated that statin exposure can induce tumour cell apoptosis, impair invasion and migration, and sensitise cells to established chemotherapeutics. Epidemiological evidence further suggests that statin users experience improved survival outcomes, supporting the repurposing of these well-tolerated agents in adjuvant settings. Ongoing research aims to elucidate the molecular determinants of response—such as p53 mutational status—and to integrate statins into multi-agent regimens, with the ultimate goal of enhancing therapeutic efficacy, overcoming resistance and reducing recurrence in women with advanced or high-grade disease.

Research from Nature Portfolio

Recent mechanistic studies have delineated how statins exploit synthetic lethality by targeting gene pairs whose concurrent disruption leads to cancer cell death. Large-scale computational screens identified statins as inhibitors of key metastatic drivers, and in vitro assays confirmed their capacity to selectively kill ovarian cancer cells harbouring specific genetic vulnerabilities. These findings provide a rigorous molecular basis for clinical translation and support the rational design of statin-based combinations in targeted subgroups.

Foundational work has evaluated the potentiation of pitavastatin by inhibitors of downstream prenylation enzymes. In ovarian cancer cell lines, pitavastatin synergises with bisphosphonates and geranylgeranyltransferase inhibitors to produce additive or synergistic growth inhibition, enhanced caspase activation and disruption of small GTPase membrane localisation. These data underscore the therapeutic value of dual blockade within the mevalonate cascade and inform the selection of partner agents for future clinical trials.

Statin Applications in Gynecological Cancer Management publication trend

The graph below shows the total number of articles in statin applications in gynecological cancer management across all publications each year (not limited to Nature Index journals).

Technical terms

HMG-CoA reductase: The enzyme that catalyses the rate-limiting step of the mevalonate pathway, targeted by statin drugs.

Mevalonate pathway: A metabolic sequence producing cholesterol and isoprenoids required for protein prenylation and cell signalling.

Synthetic lethality: A strategy in which simultaneous perturbation of two genes or pathways leads to cell death, while inhibition of either alone is non-lethal.

Prenylation: A post-translational lipid modification that facilitates membrane association of small GTPases and other signalling proteins.

High-grade serous carcinoma: The most aggressive epithelial subtype of ovarian cancer, often driven by TP53 mutations and associated with poor prognosis.

References

1. Advances in ovarian cancer treatment using a combination of statins with other drugs. Frontiers in Pharmacology (2023).
2. Mutant p53 murine oviductal epithelial cells induce progression of high-grade serous carcinoma and are most sensitive to simvastatin therapy in vitro and in vivo. Journal of Ovarian Research (2023).
3. The molecular basis of the anticancer effect of statins. Scientific Reports (2024).
4. Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells. Scientific Reports (2017).
5. Statin use is associated with improved survival in ovarian cancer: A retrospective population-based study. PLOS ONE (2017).
6. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. BMC Cancer (2010).